Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 143 participants, all of whom received lesinurad 400 mg. The trial was measuring two things: how many participants had their blood uric acid level drop below a certain threshold (6.0 mg/dL, a level often used as a treatment target in gout management), and how many unwanted medical events occurred during the study period. It is worth noting that the data shows zero participants were recorded as having "completed" the study, with all 143 listed as "not completed" — the reasons for this were not reported in the submitted data. The reported data shows that out of the 143 participants, 68 had a blood uric acid level below 6.0 mg/dL during the study. Separately, 105 treatment-emergent adverse events (that is, unwanted medical occurrences that happened after starting the study medication) were recorded across the group. No further breakdown of those adverse events — such as what types occurred or how serious they were — was included in the submitted results data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Gout Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are able to understand what the study involves and the possible risks, and you are willing to sign a consent form before any study activities begin.
- You took part in and completed a previous related study (called RDEA594-303) and were still actively taking the study medication (either lesinurad or a dummy pill) at the 6-month visit in that study.
- You are willing to follow the study schedule and attend all required visits.
- You are male or female; however, if you are a woman who could become pregnant, you must agree to use an effective non-hormonal form of birth control throughout the study and for at least 14 days after taking your last dose of study medication.
Who may not be able to join:
- You have any other medical or mental health condition that the study doctor believes could put you at unnecessary risk or make it difficult for you to follow the study rules and complete the study (confirm with trial site).
- You have a past history of kidney stones or a condition that makes you prone to developing kidney stones.
- You developed kidney stones while taking part in the previous related study (RDEA594-303).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chris Storgard, MD, Ardea Biosciences, Inc.
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL; Incidence of Treatment-emergent Adverse Events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.